Low-Dose Slow Infusion Tissue Plasminogen Activator (tPA) in Treatment of Thrombotic Coronary Artery Occlusions: Case Series and Literature Review

Akçay M., Çoksevim M., Yıldırım U., Gedikli Ö., Gülel O., Yüksel S., ...Daha Fazla

ANATOLIAN JOURNAL OF CARDIOLOGY, cilt.26, sa.4, ss.249-257, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 26 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5152/anatoljcardiol.2022.1083
  • Dergi Adı: ANATOLIAN JOURNAL OF CARDIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.249-257
  • Anahtar Kelimeler: Thrombosis, coronary artery occlusion, low-dose slow-infusion tPA, ACUTE MYOCARDIAL-INFARCTION, LEFT MAIN THROMBOSIS, VALVE THROMBOSIS, INTRACORONARY THROMBOLYSIS, THERAPY, PATIENT, INTERVENTION, REPERFUSION, ASPIRATION, MANAGEMENT
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Thrombotic coronary artery occlusions usually manifest as acute coronary syndrome with cardiogenic shock, acute pulmonary edema, cardiac arrest, fatal arrhythmias, or sudden cardiac death. Although it usually occurs based on atherosclerosis, ft can also occur without atherosclerosis. There is no predictor of coronary artery thrombosis clinically and no consensus regarding the optimal treatment. In the current literature, treatment options include emergency coronary artery bypass grafting, entrapment of thrombus in vessel wall with stent implantation, intracoronary thrombolysis, glycoprotein IIb/IIIa inhibitors, anticoagulation with heparin, and thrombus aspiration as reperfusion strategies. Here, we reviewed a new treatment strategy based on the literature, and a case series with successful results in hemodynamically stable patients with low-dose slow infusion tissue plasminogen activator (tPA) for thrombotic coronary artery occlusions that allow coronary flow was reported. Prospective randomized studies and common consensus are needed on low-dose, slow-infusion tissue plasminogen activator treatment regimen and optimal treatment management for thrombotic coronary artery occlusions.